The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...

After plugging billions into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking ...

In a recent head-to-head study involving Novo Nordisk 's Wegovy, Zepbound came out on top, resulting in average weight loss ...

“The demand for Lilly products continues to be very robust, and the stock continues to look strong longer-term despite some near-term volatility,” they wrote. “Periods of consolidation are ...

Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...

Lilly has harshly criticized the cheaper products made by compounding pharmacies — going so far as to send cease-and-desist letters to telehealth sites offering compounded products.

Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are demonstrably more effective in clinical trials. The most recent earnings reports ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Eli Lilly's robust product portfolio ... and oncology markets. LLY’s key products, Mounjaro and Zepbound, dominate the U.S. weight-loss market, contributing significantly to revenue and long ...

Chris Schott, an analyst from J.P. Morgan, maintained the Buy rating on Eli Lilly & Co (LLY – Research Report). The associated price target ...